| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Isochenodeoxycholic acid does not have a distinct therapeutic protein target but acts via its physicochemical properties as a bile acid. It interacts with membrane lipids (detergent effect) and activates nuclear receptors such as FXR (Farnesoid X Receptor) and TGR5, though typically with different potency compared to its more common epimer, ursodeoxycholic acid (UDCA).
|
|---|---|
| ln Vitro |
In vitro, isoCDCA activates bile acid receptors, which can be measured in reporter gene assays. It also modulates lipid metabolism in cultured hepatocytes, affecting the expression of genes involved in cholesterol synthesis and bile acid transport. It is used as a metabolite standard to verify the purity of UDCA preparations via HPLC.
|
| ln Vivo |
As a secondary bile acid, its in vivo activity is related to the regulation of lipid and cholesterol metabolism when administered exogenously. It can promote bile flow (choleresis) and influence the intestinal absorption of fats and fat-soluble vitamins, mirroring the general physiological roles of other dihydroxy bile acids in the enterohepatic circulation.
|
| Enzyme Assay |
Isochenodeoxycholic acid is primarily used as a reference compound in analytical chemistry assays. A non-cellular HPLC method is used for its identification and quantification. A reference standard of isoCDCA is dissolved in mobile phase (e.g., acetonitrile-phosphate buffer) and injected into an HPLC system with a C18 reverse-phase column. Its retention time and UV absorbance spectrum are compared to a standard curve.
|
| Cell Assay |
The compound is not typically tested in functional cellular assays as a primary screen. Instead, it is used as an analytical spike-in control. For example, cell lysates or serum samples are spiked with a known concentration of isoCDCA, and the sample is processed for LC-MS/MS analysis. The recovery of the spiked isoCDCA validates the efficiency of the analytical method for detecting bile acids in biological matrices.
|
| Animal Protocol |
In vivo animal protocols for isoCDCA are limited, as it is not a therapeutic candidate. It can be administered intravenously or orally to bile duct-cannulated rats to study bile flow (choleretic effect). For analytical method validation, it is administered to mice or rats (e.g., 10-50 mg/kg oral gavage), and serial blood and bile samples are collected over 24-48 hours to confirm the detection limits of an LC-MS/MS assay.
|
| ADME/Pharmacokinetics |
As a secondary bile acid, isoCDCA is passively absorbed from the intestine and undergoes enterohepatic recirculation. It is conjugated with glycine or taurine in the liver and re-secreted into the bile. Its plasma half-life is short (minutes to hours). It is not a drug candidate; its PK properties are characterized for analytical purposes to support impurity profiling.
|
| Toxicity/Toxicokinetics |
Isochenodeoxycholic acid is considered an impurity or metabolite in pharmaceutical-grade UDCA. Its toxicity profile is not documented as a standalone compound, but as a bile acid, very high levels can cause cholestasis (impaired bile flow) and hepatotoxicity due to its detergent properties. It is not intended for direct human consumption as a therapeutic agent.
|
| References |
[1]. Marschall HU, et al. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J Lipid Res. 2001 May;42(5):735-42.
|
| Additional Infomation |
3β,7α-Dihydroxy-5β-cholan-24-acid is a dihydroxy-5β-cholanic acid, wherein the two hydroxyl groups are located at the 3β and 7α positions, respectively. It is the 3β-hydroxy epimer of chenodeoxycholic acid. It plays a role in human metabolism. It is a bile acid, a 7α-hydroxy steroid, a 3β-hydroxy steroid, and a dihydroxy-5β-cholanic acid. It is the conjugate acid of 3β,7α-dihydroxy-5β-cholan-24-acid.
IsoCDCA is primarily used as a pharmaceutical reference standard for quality control in the production of ursodeoxycholic acid (UDCA). It is an epimer of chenodeoxycholic acid and is listed as an impurity (Impurity K) in pharmacopoeial monographs (e.g., EP). It has no therapeutic application or drug approval status. |
| Molecular Formula |
C24H40O4
|
|---|---|
| Molecular Weight |
392.57
|
| Exact Mass |
392.293
|
| CAS # |
566-24-5
|
| PubChem CID |
164673
|
| Appearance |
White to off-white solid powder
|
| Source |
bile acids
|
| LogP |
4.477
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
605
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
|
| InChi Key |
RUDATBOHQWOJDD-JGFDLHJZSA-N
|
| InChi Code |
InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16+,17-,18+,19+,20-,22+,23+,24-/m1/s1
|
| Chemical Name |
(4R)-4-[(3S,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~254.7 mM; with ultrasonication)
Ethanol: ~8.3 mg/mL (~21.2 mM; with ultrasonication) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.11 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (8.3 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.11 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of ethanol stock solution (8.3 mg/mL) to 900 μL of 20% SBE-β-CD physiological saline and mix well. Preparation of 20% SBE-β-CD physiological saline (4°C, store for one week): Dissolve 2 g of SBE-β-CD powder in 10 mL of physiological saline until completely dissolved and clear. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 0.83 mg/mL (2.11 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of EtOH stock solution (8.3 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5473 mL | 12.7366 mL | 25.4732 mL | |
| 5 mM | 0.5095 mL | 2.5473 mL | 5.0946 mL | |
| 10 mM | 0.2547 mL | 1.2737 mL | 2.5473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
